BlueFocus (300058.SZ): board resolves to terminate H-share offering and HKEX listing, sees no material adverse impact
NewTimeSpace News: BlueFocus (300058.SZ) announced that on 26 October 2026 the Company convened the fifth meeting of the seventh session of the Board, at which it considered and approved the resolution on terminating the issuance of H shares and the listing on The Stock Exchange of Hong Kong Limited, agreeing to terminate the H-share offering and the Hong Kong listing. The Company said the matter falls within the scope of the mandate granted by the shareholders' meeting authorising the Board to handle it at its full discretion, and does not require submission to the shareholders' meeting for approval.
According to the announcement, the Company had previously convened the 19th meeting of the sixth session of the Board on 6 June 2025 and the second extraordinary general meeting of 2025 on 23 June 2025, at which it approved the resolution on the issuance of H shares and the listing on The Stock Exchange of Hong Kong Limited and the resolution on authorising the Board and its authorised persons to handle matters relating to the H-share offering and listing. The relevant announcements were published on the CNINFO website on 7 June 2025 and 23 June 2025.
The Company said the termination was made after prudent discussion and analysis based on a comprehensive consideration of the market environment and its own development plan, and in line with the principles of safeguarding shareholders' interests and being accountable to shareholders. It said its operations remain stable and orderly, and that the termination is a prudent decision reached after comprehensively weighing multiple factors and the actual situation; it will not have a material adverse impact on the Company's daily production and operations, business layout or sustainable development, and does not involve any circumstance prejudicial to the interests of the Company and its shareholders as a whole, particularly minority shareholders. Investors are advised to note the investment risks.
- LONTIUM (688486.SH): CSRC accepts H-share filing, up to 23,878,000 shares for HKEX Main Board listing
- CHALIECO (02068.HK): wins EPC contract for 2.4 mtpa alumina project in Vietnam, contract price USD833 million
- CH GENERAL EDU (02175.HK): sets up wholly-owned unit to run AIGC training for art and design students
- CSPC PHARMA (01093.HK): Anbenitamab plus HB1801 hits Phase III endpoint, 54% lower risk of progression, first NEJM breast cancer paper from mainland China
- ROBOTECHNIK (03757.HK): H shares included in Stock Connect eligible securities list from 26 October